explore -WSS

explore

author：explore 2025-10-01 01:00:14 - browse：55237

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Mindstrong's demise and the future of mental health care

WSS

Senator probes 340B programs at Cleveland Clinic, Bon Secours

FTC sues over Novant Health acquisition of two N.C. hospitals

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Reconstructing family trees of blood cells may help predict disease

Pancreatic cancer early detection could be helped by AI

Philips to halt sales of sleep apnea machines in U.S.

entertainment

explore

Wikipedia

Supreme Court strikes down use of affirmative action

Medicare drug price negotiation legal challenge met with skepticism

Medicare proposal to cover medical devices draws a mixed reaction

Address the ethical violations that led to 'Three Identical Strangers'

Heart attack and stroke risk calculators need revising

10 reasons why health care startups fail

Psychedelics group wrestles with new pharma identity

Intercept Pharmaceuticals sells itself for less than $1 billion

Hepatitis C has a cure — but many Americans still lack access to it

Paxlovid should be available without a positive Covid test

focus

Bernie Sanders is gearing up to subpoena pharma CEOs

Medicaid, Medicare dual

FTC sues over Novant Health acquisition of two N.C. hospitals

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Boston competes with Raleigh

Did you have Obamacare on your GOP debate bingo card?

entertainment

Wikipedia

hotspot

leisure time